6. Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI)
Number of Hedge Fund Holders: 33
Market Capitalization: $2.14 billion
Share Price: $8.26
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) approaches biotechnology from the supply side. It provides reagents, nucleic acid technologies, and testing products used by researchers and drug developers, offering exposure to industry activity across multiple customer programs.
The shares had rallied more than 100%, according to the supplied material, as improving business performance renewed interest in the company’s role in the mRNA ecosystem.
TriLink is the main growth engine. Its second-quarter revenue increased 11.5% to approximately $34.7 million, supported by demand for discovery materials and consumables manufactured to standards required for clinical development. First-half revenue rose 37.3% to approximately $82.1 million.
The composition of that growth is worth examining. Large CleanCap orders for commercial COVID vaccine programs contributed to the first-half increase. Excluding COVID-related CleanCap revenue, TriLink’s base revenue grew 13.4%, providing a clearer view of demand outside that established application.
The broader business also supplies biologics safety-testing products through its Cygnus segment. These tools help manufacturers assess impurities and product quality, connecting the company to another recurring requirement in drug production.
On October 5, TD Cowen initiated coverage with a Buy rating and a $9 price target, highlighting non-COVID mRNA applications and CleanCap revenue opportunities.
Improvement has not yet eliminated losses. Second-quarter consolidated revenue was approximately $51.4 million, while the company reported a $21.6 million net loss. Investors therefore need to weigh revenue momentum against the pace of progress toward sustainable earnings.
Ranking rationale: Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) places sixth with 33 hedge-fund holders. Its specialized manufacturing inputs and testing products provide a distinct biotechnology investment case, supported by improving demand but still dependent on stronger operating performance.
YOU MUST READ THIS: 10 Promising Small-Cap Biotech Stocks to Watch
Click here to continue reading and checkout the 5 Best Biotech Stocks Under $10 to Buy Now.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
